Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Pithy intro text about the biopharma milieu.
Novartis cites more tumor reports after Zolgensma
Novartis has disclosed seven previously unreported cases of tumors in children who received Zolgensma, its gene therapy for spinal muscular atrophy. The company has received nine tumor reports in all since the treatment was approved in 2019, STAT’s Ed Silverman and Jason Mast write.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
Source: www.statnews.com
